Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles

被引:29
作者
Kim, SC
Yoon, HJ
Lee, JW
Yu, JW
Park, ES
Chi, SC
机构
[1] Samyang Res Co, Sandy, UT 84070 USA
[2] Samyang Co, Seoul 110725, South Korea
[3] Sungkyunkwan Univ, Coll Pharm, Suwon 440746, South Korea
关键词
di-(2-ethylhexyl) phthalate; PVC; paclitaxel (Taxol((R))); polymeric micelles; mPEG-PDLLA;
D O I
10.1016/j.ijpharm.2005.01.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current clinical formulation of paclitaxel (Taxol (R)) contains 1: 1 blend of Cremophore EL (polyethoxylated castor oil) and dehydrated ethanol. Cremophore EL and dehydrated ethanol are well known to leach di-(2-ethylhexyl) phthalate (DEHP) from polyvinyl chloride (PVC) infusion bags and PVC administration sets. DEHP is a possible hepatotoxin, carcinogen, teratogen and mutagen. Long-term exposure to DEHP may cause health risks. As an alternative formulation for paclitaxel, paclitaxel-loaded polymeric micelles (PLPM), made of monomethoxy poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-PDLLA) diblock copolymer, has demonstrated clear advantages over Taxol (R) in pharmacokinetics and therapeutic index. Paclitaxel in either PLPM or Taxol (R) formulations, diluted in 0.9% sodium chloride injection, was stable in the PVC infusion bags. The PLPM formulation significantly reduced the amount of DEHP extracted from PVC infusion bags and PVC administration sets. For PLPM diluted in 0.9% sodium chloride injection, the total amount of DEHP delivered over the simulated infusion period was 0.7 mg for 3 h and 2.0 mg for 24 h, which was less than 2.9% of the DEHP extracted by Taxol (R). These results confirmed that there is negligible risk of DEHP exposure from diluted PLPM i.v. infusion using PVC infusion bags and PVC administration sets. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:303 / 310
页数:8
相关论文
共 48 条
[1]  
*BMS, 2003, TAX PACL PACK INS
[2]   Development of copolymers of poly(D,L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel [J].
Burt, HM ;
Zhang, XC ;
Toleikis, P ;
Embree, L ;
Hunter, WL .
COLLOIDS AND SURFACES B-BIOINTERFACES, 1999, 16 (1-4) :161-171
[3]   TOXICOLOGY OF A SERIES OF PHTHALATE ESTERS [J].
CALLEY, D ;
AUTIAN, J ;
GUESS, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1966, 55 (02) :158-&
[4]  
Chi SC, 2003, ARCH PHARM RES, V26, P173
[5]   SYNTHESIS AND CHARACTERIZATION OF BLOCK COPOLYMERS FROM D,L-LACTIDE AND POLY(ETHYLENE GLYCOL) WITH STANNOUS CHLORIDE [J].
DENG, XM ;
XIONG, CD ;
CHENG, LM ;
XU, RP .
JOURNAL OF POLYMER SCIENCE PART C-POLYMER LETTERS, 1990, 28 (13) :411-416
[6]   PHTHALATE-ESTERS AND THEIR EFFECT ON THE LIVER [J].
GANNING, AE ;
BRUNK, U ;
DALLNER, G .
HEPATOLOGY, 1984, 4 (03) :541-547
[7]   NONLINEAR PHARMACOKINETICS AND METABOLISM OF PACLITAXEL AND ITS PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS IN HUMANS [J].
GIANNI, L ;
KEARNS, CM ;
GIANI, A ;
CAPRI, G ;
VIGANO, L ;
LOCATELLI, A ;
BONADONNA, G ;
EGORIN, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :180-190
[8]  
GREGORY RE, 1993, CLIN PHARMACY, V12, P401
[9]   Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (pluronic)/poly(ε-caprolactone) (PCL) amphiphilic block copolymeric nanospheres -: I.: Preparation and characterization [J].
Ha, JC ;
Kim, SY ;
Lee, YM .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (03) :381-392
[10]  
HAGEN S., 1996, LANGMUIR, V12, P2153